• Breast cancer is the second most common cancer in the world and, by far, the most frequent cancer among women with an estimated 1.67 million new cancer cases diagnosed in 2012 (522,000 deaths), which represents 25% of all cancers.
• Its use in clinical practice in France is limited because of the absence of reimbursement.
OBJECTIVE
• This study aims to determine if the utilisation of the 21-gene assay in private hospitals would provide good value for money from a collective perspective in France and whether hospitals can afford using the test under the current payment system.
METHODS
Collection of cost data A multicentre retrospective study was conducted in seven French private hospitals, all part of the Générale de Santé group, to estimate the cost of adjuvant chemotherapy from societal and national insurance perspectives.
• Resource data were extracted from medical records of female patients who have undergone surgery for breast cancer from January 2008 to January 2013.
• The inclusion criteria were:
 Women who received all cycles of chemotherapy within the same private hospital  Women with ER+, negative HER2 status and no node involvement
• Patients were followed from the start (including the pre-chemotherapy period) to the end of adjuvant chemotherapy.
• Patients characteristics and pre-chemotherapy tests and biological procedures information were collected.
• Data on chemotherapy regimen, prophylactic agents, side effects visits, hospitalizations, laboratory tests, home care, transport and sick leave were collected at each chemotherapy cycle.
• Unit costs were expressed in 2013 Euros (€).
Cost-effectiveness analysis
• The estimate of the cost of chemotherapy resulting from the cost study was used as an input of a Markov model to assess the cost-effectiveness of the 21-gene assay from the French collective perspective.
• The model included three health states: survival without recurrence, metastatic recurrence and death. All patients started simulation in the state "without recurrence" (Figure 1 ). The model cycle length was one year with a time horizon of 30 years.
• The considered health outcomes were life-years and quality-adjusted life-years (QALYs). To calculate QALYs, utility decrements (-0.07) were applied for patients undergoing chemotherapy and after recurrence. [3] Future costs and clinical benefits were discounted at 4% per annum.
• Other model inputs were the same as in a previous cost-effectiveness model of the 21-gene assay in France. [4] Financial impact for hospitals
• The marginal revenue was defined as the revenue generated by one patient with adjuvant chemotherapy, and was estimated based on data collected in the different hospitals.
• The impact of introducing the 21-gene assay on the total revenue of a private hospital was calculated, assuming 100 patients with breast cancer were admitted for surgical intervention over a one year period.
• Two scenarios were compared: with and without the use of the 21-gene assay for eligible women.
• The proportion of women eligible for the test was estimated at 43.4% ( Figure 2 ). [5] • The hospitals net profit margin was 2.9%, based on the 2012 annual report published by Générale de Santé. [6] Vataire AL 1 , Aballéa S 1 , Katz G • In the absence of reimbursement from primary payers, private hospitals may cover the costs of companion diagnostics to improve their attractiveness.
• Due to budget constraints, the test will likely remained underused, thus depriving patients from a technology that could improve their quality of life and using resources that could be freed up for other patients.
RESULTS
• Cost study results  A total of 106 patients were included, with a mean age of 53.2 years.  62.1% were employed, 27.1% were retired and 10.8% were unemployed. Amongst employed patients, 90.7% took sick leave during the entire chemotherapy episode.
 The most frequent treatment protocol was found to be a combination of epirubicine, cyclophosphamide and fluorouracil (5-FU) (47.5% of all cycles), followed by docetaxel (27.6% of cycles).
 The most frequent prescriptions for prevention of adverse events were antiemetics (92% of cycles) and growth factors (58% of cycles).
 Over the 577 cycles, 32 hospitalisations occurred, mainly in medicine services (25%) and surgical wards (25%), involving 19% of patients.
 The mean cost of adjuvant chemotherapy was estimated at €10,305 per patient from a societal perspective and €8,218 from a payer perspective (Table 1) .
 The main cost driver was work absenteeism, which accounted for 39% of total costs from a societal perspective, and 24% from a payer perspective.
 Other important cost drivers included prophylactic prescriptions: 24% of total societal costs and 30% of payer costs and chemotherapy administration costs (15% of total societal costs and 19% of payer costs).
Cost components
Payer • Financial impact for hospitals  The changes in treatment prescriptions generated an average net loss in revenues of chemotherapy of €779 per patient tested, resulting from a loss of €908 due to chemotherapies avoided and a gain of €129 due to additional chemotherapies (Table 3 and Figure 2  The test acquisition cost (€3,180) was partly offset by reductions in chemotherapy costs, estimated at €1,508 on average per patient, and costs related to recurrences (€1,319).
 When productivity costs were included, using the 21-gene assay was associated with an overall cost saving of €602 per patient ( 
